| Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. | |
| | |
MedLine Citation:
|
PMID: 12727925 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Primary pulmonary hypertension is a fatal disease causing progressive right heart failure within 3 years after diagnosis. We describe a new concept for treatment of the disease using vasoactive intestinal peptide, a neuropeptide primarily functioning as a neurotransmitter that acts as a potent systemic and pulmonary vasodilator. Our rationale is based on the finding of a deficiency of the peptide in serum and lung tissue of patients with primary pulmonary hypertension, as evidenced by radioimmunoassay and immunohistochemistry. The relevance of this finding is underlined by an upregulation of corresponding receptor sites as shown by Northern blot analysis, Western blot analysis, and immunological techniques. Consequently, the substitution with the hormone results in substantial improvement of hemodynamic and prognostic parameters of the disease without side effects. It decreased the mean pulmonary artery pressure in our eight study patients, increased cardiac output, and mixed venous oxygen saturation. Our data provide enough proof for further investigation of vasoactive intestinal peptide and its role in primary pulmonary hypertension. |
| | |
Authors:
|
Ventzislav Petkov; Wilhelm Mosgoeller; Rolf Ziesche; Markus Raderer; Leopold Stiebellehner; Karin Vonbank; Georg-Christian Funk; Gerhard Hamilton; Clemens Novotny; Bernhard Burian; Lutz-Henning Block |
Related Documents
:
|
16728715 - Hiv-1 nef is associated with complex pulmonary vascular lesions in shiv-nef-infected ma... 2705865 - Pulmonary endocrine cells in pulmonary arterial disease. 1149525 - A radiologic index of pulmonary arterial hypertension. 8976545 - Plasma norepinephrine increased during coronary occlusion in hypertensive pigs that dev... 3880535 - Allergic bronchopulmonary aspergillosis. 23272885 - Hybrid approach for aneurysm of patent ductus arteriosus in an adult. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The Journal of clinical investigation Volume: 111 ISSN: 0021-9738 ISO Abbreviation: J. Clin. Invest. Publication Date: 2003 May |
Date Detail:
|
Created Date: 2003-05-02 Completed Date: 2003-06-05 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 7802877 Medline TA: J Clin Invest Country: United States |
Other Details:
|
Languages: eng Pagination: 1339-46 Citation Subset: AIM; IM |
Affiliation:
|
Department of Internal Medicine, University of Vienna, Medical School, Vienna, Austria. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Cell Division / physiology Cells, Cultured Exercise Female Hemodynamics Humans Hypertension, Pulmonary / blood, drug therapy*, metabolism, physiopathology Immunohistochemistry Lung / metabolism, pathology Male Middle Aged Muscle, Smooth, Vascular / metabolism, pathology Myocytes, Smooth Muscle / pathology, physiology Radioligand Assay Receptors, Vasoactive Intestinal Peptide / genetics, metabolism Receptors, Vasoactive Intestinal Peptide, Type II Receptors, Vasoactive Intestinal Polypeptide, Type I Vasoactive Intestinal Peptide / blood, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Receptors, Vasoactive Intestinal Peptide; 0/Receptors, Vasoactive Intestinal Peptide, Type II; 0/Receptors, Vasoactive Intestinal Polypeptide, Type I; 37221-79-7/Vasoactive Intestinal Peptide |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inf...
Next Document: Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.